Faculty Opinions recommendation of Low Birth Weight and Risk of Progression to End Stage Renal Disease in IgA Nephropathy--A Retrospective Registry-Based Cohort Study.

Author(s):  
Luis Ruilope ◽  
Enrique Morales
PLoS ONE ◽  
2016 ◽  
Vol 11 (4) ◽  
pp. e0153819 ◽  
Author(s):  
Paschal Ruggajo ◽  
Einar Svarstad ◽  
Sabine Leh ◽  
Hans-Peter Marti ◽  
Anna Varberg Reisæther ◽  
...  

2013 ◽  
Vol 84 (5) ◽  
pp. 1017-1024 ◽  
Author(s):  
Sean J. Barbour ◽  
Daniel C. Cattran ◽  
S Joseph Kim ◽  
Adeera Levin ◽  
Ron Wald ◽  
...  

2020 ◽  
Vol 21 (23) ◽  
pp. 9064
Author(s):  
Dita Maixnerova ◽  
Vladimir Tesar

IgA nephropathy is the most common primary glomerulonephritis with potentially serious outcome leading to end stage renal disease in 30 to 50% of patients within 20 to 30 years. Renal biopsy, which might be associated with risks of complications (bleeding and others), still remains the only reliable diagnostic tool for IgA nephropathy. Therefore, the search for non-invasive diagnostic and prognostic markers for detection of subclinical types of IgA nephropathy, evaluation of disease activity, and assessment of treatment effectiveness, is of utmost importance. In this review, we summarize treatment options for patients with IgA nephropathy including the drugs currently under evaluation in randomized control trials. An early initiation of immunosupressive regimens in patients with IgA nephropathy at risk of progression should result in the slowing down of the progression of renal function to end stage renal disease.


2018 ◽  
Vol 38 (4) ◽  
pp. 347-352
Author(s):  
Manuel Praga ◽  
Fernando Caravaca ◽  
Claudia Yuste ◽  
Teresa Cavero ◽  
Eduardo Hernández ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document